Flavia Longo

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: Chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours and progression-free survival was significantly better with docetaxel than with erlot inib.

TL;DR: The persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape, and patients could be dichotomized into two groups based PD- L1 expression on C TCs, which suggests that the persistence ofPD-L2 negative CTCS all obtained a clinical benefit, while patients with PD-CTCs all experienced progressive disease.

TL;DR: Multimodality treatment with induction chemotherapy (when required) and adjuvant chemoradiotherapy offers encouraging results for stage III thymic tumors; the outcome is more favorable for cortical thymoma and well-differentiatedThymic carcinoma.

TL;DR: Perfusion CT imaging may allow evaluation of lung cancer angiogenesis demonstrating alterations in vascularity following treatment, and Pearson correlation coefficient showed a significant correlation between baseline values of blood flow and blood volume and CT numbers.